

## References

1. Blackadar CB. Historical review AQ6 of the causes of cancer. *World J Clin Oncol* 2016;7:54–86.
2. Lathwal A, Kumar R, Raghava GPS. Computer-aided designing of oncolytic viruses for overcoming translational challenges of cancer immunotherapy. *Drug Discov Today* 2020;25:1198–205.
3. Subramanian I, Verma S, Kumar S, et al. Multi-omics data integration, interpretation, and its application. *Bioinform Biol Insights* 2020;14:1177932219899051.
4. Kumar R, Lathwal A, Kumar V, et al. CancerEnD: a database of cancer associated enhancers. *Genomics* 2020;112:3696–702.
5. Zhang B, Wang J, Wang X, et al. Proteogenomic characterization of human colon and rectal cancer. *Nature* 2014;513:382–7.
6. Goodwin S, McPherson JD, McCombie WR. Coming of age:ten years of next-generation sequencing technologies. *Nat Rev Genet* 2016;17:333–51.
7. Petersen BS, Fredrich B, Hoepfner MP, et al. Opportunities and challenges of whole-genome and exome sequencing. *AQ7 BMC Genet* 2017;18; :108-120.
8. Das T, Andrieux G, Ahmed M, et al. Integration of online omics-data resources for cancer research. *Front Genet* 2020;11:578345.
9. Nagarajan RP, Fouse SD, Bell RJA, et al. Methods for cancer epigenome analysis. *Adv Exp Med Biol* 2013;754:313–38.
10. Prieto DA, Johann DJ, Wei BR, et al. Mass spectrometry in cancer biomarker research: a case for immunodepletion of abundant blood-derived proteins from clinical tissue specimens. *Biomark Med* 2014;8:269–86.
11. Bohnenberger H, Ströbel P, Mohr S, et al. Quantitative mass spectrometric profiling of cancer-cell proteomes derived from liquid and solid tumors. *J Vis Exp* 2015;e52435.
12. Barrett T, Wilhite SE, Ledoux P, et al. NCBI GEO: archive for functional genomics data sets - update. *Nucleic Acids Res* 2013;41:D991–5.
13. Hudson TJ, Anderson W, Aretz A, et al. International network of cancer genome projects. *Nature* 2010;464:993–8.
14. Leinonen R, Sugawara H, Shumway M. The sequence read archive. *Nucleic Acids Res* 2011;39:D19–21.

15. Bamford S, Dawson E, Forbes S, et al. The COSMIC (catalogue of somatic mutations in cancer) database and website. *Br J Cancer* 2004;91:355–8.
16. Yao D, Zhang L, Zheng M, et al. Circ2Disease: a manually curated database of experimentally validated circRNAs in human disease. *Sci Rep* 2018;8:11018.
17. Ghosal S, Das S, Sen R, et al. Circ2Traits: a comprehensive database for circular RNA potentially associated with disease and traits. *Front Genet* 2013;4:283.
18. Vo JN, Cieslik M, Zhang Y, et al. The landscape of circular RNA in cancer. *Cell* 2019;176:869–881.e13.
19. Li S, Li Y, Chen B, et al. ExoRBase: a database of circRNA, lncRNA and mRNA in human blood exosomes. *Nucleic Acids Res* 2018;46:D106–12.
20. Bao Z, Yang Z, Huang Z, et al. LncRNADisease 2.0: an updated database of long non-coding RNA-associated diseases. *Nucleic Acids Res* 2019;47:D1034–7.
21. Liu YC, Li JR, Sun CH, et al. CircNet: a database of circular RNAs derived from transcriptome sequencing data. *Nucleic Acids Res* 2016;44:D209–15.
22. Ruan H, Xiang Y, Ko J, et al. Comprehensive characterization of circular RNAs in ~ 1000 human cancer cell lines. *Genome Med* 2019;11:55.
23. Zeng X, Lin W, Guo M, et al. A comprehensive overview and evaluation of circular RNA detection tools. *PLoS Comput Biol* 2017;13:e1005420.
24. Vromman M, Vandesompele J, Volders P-J. Closing the circle: current state and perspectives of circular RNA databases. *Brief Bioinform* 2020;22:288–297.
25. Jensen MA, Ferretti V, Grossman RL, et al. The NCI genomic data commons as an engine for precision medicine. *Blood* 2017;130:453–9.
26. Zhang J, Baran J, Cros A, et al. International cancer genome consortium data portal—a one-stop shop for cancer genomics data. *Database* 2011;2011:bar026.
27. Brazma A, Parkinson H, Sarkans U, et al. ArrayExpress – a public repository for microarray gene expression data at the EBI. *Nucleic Acids Res* 2003;31:68–71.
28. Zhu J, Sanborn JZ, Benz S, et al. The UCSC cancer genomics browser. *Nat Methods* 2009;6:239–40.
29. Feng X, Li L, Wagner EJ, et al. TC3A: the cancer 3' UTR atlas. *Nucleic Acids Res* 2018;46:D1027–30.

30. Lee M, Lee K, Yu N, et al. ChimerDB 3.0: an enhanced database for fusion genes from cancer transcriptome and literature data mining. *Nucleic Acids Res* 2017;45:D784–9.
31. Vasaikar SV, Straub P, Wang J, et al. LinkedOmics: Analyzing multi-omics data within and across 32 cancer types. *Nucleic Acids Res* 2018;46:D956–63.
32. Ryan M, Wong WC, Brown R, et al. TCGASpliceSeq a compendium of alternative mRNA splicing in cancer. *Nucleic Acids Res* 2016;44:D1018–22.
33. Halling-Brown MD, Bulusu KC, Patel M, et al. canSAR: an integrated cancer public translational research and drug discovery resource. *Nucleic Acids Res* 2012;40:D947–56.
34. Packer BR, Yeager M, Burdett L, et al. SNP500Cancer: a public resource for sequence validation, assay development, and frequency analysis for genetic variation in candidate genes. *Nucleic Acids Res* 2006;34:D617–21.
35. Samur MK, Yan Z, Wang X, et al. canEvolve: a web portal for integrative Oncogenomics. *PLoS One* 2013;8:e56228.
36. Liu SH, Shen PC, Chen CY, et al. DriverDBv3: a multi-omics database for cancer driver gene research. *Nucleic Acids Res* 2020;48:D863–70.
37. Ru B, Sun J, Tong Y, et al. CR2Cancer: a database for chromatin regulators in human cancer. *Nucleic Acids Res* 2018;46:D918–24.
38. Yang W, Soares J, Greninger P, et al. Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. *Nucleic Acids Res* 2013;41:D995–61.
39. Barretina J, Caponigro G, Stransky N, et al. The cancer cell line Encyclopedia enables predictive modelling of anti-cancer drug sensitivity. *Nature* 2012;483:603–7.
40. Sun X, Pittard WS, Xu T, et al. Omicseq: a web-based search engine for exploring omics datasets. *Nucleic Acids Res* 2017;45:W445–52.
41. Lee L, Wang K, Li G, et al. Liverome: A curated database of liver cancer-related gene signatures with self-contained context information. *BMC Genomics*. 2011 Nov 30;12 Suppl 3(Suppl 3):S3.
42. Bhalla S, Verma R, Kaur H, et al. CancerPDF: a repository of cancer-associated peptidome found in human biofluids. *Sci Rep* 2017;7:1511.
43. Tyagi A, Tuknait A, Anand P, et al. CancerPPD: a database of anticancer peptides and proteins. *Nucleic Acids Res* 2015;43:D837–43.

44. Zhang X, Sun XF, Cao Y, et al. CBD: a biomarker database for colorectal cancer. *Database* 2018;2018: bay046.
45. Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov* 2012;2:401–4.
46. Zheng G, Ma Y, Zou Y, et al. HCMDB: the human cancer metastasis database. *Nucleic Acids Res* 2018;46:D950–5.
47. Kumar R, Chaudhary K, Gupta S, et al. CancerDR: cancer drug resistance database. *Sci Rep* 2013;3:1445.
48. Bhattacharya A, Cui Y. SomamiR 2.0: a database of cancer somatic mutations altering microRNA-ceRNA interactions. *Nucleic Acids Res* 2016;44:D1005–10.
49. Dingerdissen HM, Bastian F, Vijay-Shanker K, et al. OncoMX: a knowledgebase for exploring cancer biomarkers in the context of related cancer and healthy data. *JCO Clin Cancer Informatics* 2020;4:210–20.
50. Pérez-Granado J, Piñero J, Furlong LI. ResMarkerDB: a database of biomarkers of response to antibody therapy in breast and colorectal cancer. *Database* 2019;2019: baz060.
51. Kaur H, Bhalla S, Kaur D, et al. CancerLivER: a database of liver cancer gene expression resources and biomarkers. *Database (Oxford)* 2020;2020: baaa012..
52. Lian Q, Wang S, Zhang G, et al. HCCDB: a database of hepatocellular carcinoma expression atlas. *Genomics. Proteomics Bioinforma* 2018;16:269–75.
53. Chu YW, Chien CH, Sung MI, et al. DBMHCC: a comprehensive hepatocellular carcinoma (HCC) biomarker database provides a reliable prediction system for novel HCC phosphorylated biomarkers. *PLoS One* 2020;15:e0234084.
54. Kumar R, Raghava GPS. ApoCanD: database of human apoptotic proteins in the context of cancer. *Sci Rep* 2016;6:20797.
55. Nagpal G, Sharma M, Kumar S, et al. PCMdb: pancreatic cancer methylation database. *Sci Rep* 2014;4:4197.
56. Agarwal SM, Raghav D, Singh H, et al. CCDB: a curated database of genes involved in cervix cancer. *Nucleic Acids Res* 2011;39:D975–9.
57. Mason MJ, Schinke C, Eng CLP, et al. Multiple myeloma DREAM challenge reveals epigenetic regulator PHF19 as marker of aggressive disease. *Leukemia* 2020;34:1866–74.

58. Vidyarthi A, Agnihotri T, Khan N, et al. Predominance of M2 macrophages in gliomas leads to the suppression of local and systemic immunity. *Cancer Immunol Immunother* 2019;68:1995–2004.
59. Bhalla S, Kaur H, Kaur R, et al. Expression based biomarkers and models to classify early and late-stage samples of papillary thyroid carcinoma. *PLoS One* 2020;15:e0231629.
60. Lathwal A, Kumar R, Arora C, et al. Identification of prognostic biomarkers for major subtypes of non-small-cell lung cancer using genomic and clinical data. *J Cancer Res Clin Oncol* 2020;146:2743–52.
61. Lathwal A, Arora C, Raghava GPS. Prediction of risk scores for colorectal cancer patients from the concentration of proteins involved in mitochondrial apoptotic pathway. *PLoS One* 2019;14:e0217527.
62. Arora C, Kaur D, Lathwal A, et al. Risk prediction in cutaneous melanoma patients from their clinico-pathological features: superiority of clinical data over gene expression data. *Heliyon* 2020;6:e04811.
63. Kaur H, Dhall A, Kumar R, et al. Identification of platform-independent diagnostic biomarker panel for hepatocellular carcinoma using large-scale transcriptomics data. *Front Genet* 2019;10:1306.
64. Dhall A, Patiyal S, Kaur H, et al. Computing skin cutaneous melanoma outcome from the HLA-alleles and clinical characteristics. *Front Genet* 2020;11:221.
65. Bhalla S, Kaur H, Dhall A, et al. Prediction and analysis of skin cancer progression using genomics profiles of patients. *Sci Rep* 2019;9:15790.
66. Kaur H, Bhalla S, Garg D, et al. Analysis and prediction of cholangiocarcinoma from transcriptomic profile of patients. *J Hepatol* 2020;73:S16–7.
67. Hua X, Xu H, Yang Y, et al. DrGaP: a powerful tool for identifying driver genes and pathways in cancer sequencing studies. *Am J Hum Genet* 2013;93:439–51.
68. Palmisano A, Krushkal J, Li MC, et al. Bioinformatics tools and resources for cancer immunotherapy study. *Methods Mol Biol* 2020;2055:649–78.
69. Lathwal A, Kumar R, Raghava GPS. OvirusTdb: a database of oncolytic viruses for the advancement of therapeutics in cancer. *Virology* 2020;548:109–16.
70. Chaudhary K, Poirion OB, Lu L, et al. Deep learning-based multi-omics integration robustly predicts survival in liver cancer. *Clin Cancer Res* 2018;24:1248–59.

71. Yan Z, Wang Q, Lu Z, et al. OSluca: an interactive web server to evaluate prognostic biomarkers for lung cancer. *Front Genet* 2020;11:420.
72. Dong H, Wang Q, Li N, et al. OSgbm: an online consensus survival analysis web server for glioblastoma. *Front Genet* 2020;10:1378.
73. Bhalla S, Chaudhary K, Kumar R, et al. Gene expression-based biomarkers for discriminating early and late stage of clear cell renal cancer. *Sci Rep* 2017;7:44997.
74. Kaur H, Bhalla S, Raghava GPS. Classification of early and late stage liver hepatocellular carcinoma patients from their genomics and epigenomics profiles. *PLoS One* 2019;14:e0221476.
75. Bhalla S, Chaudhary K, Gautam A, et al. A web bench for analysis and prediction of oncological status from proteomics data of urine samples. *bioRxiv* 2018;315564 May 15, 2018. doi: 10.1101/315564 preprint: not peer reviewed.
76. Zuo Z, Hu H, Xu Q, et al. BBCancer: an expression atlas of blood-based biomarkers in the early diagnosis of cancers. *Nucleic Acids Res* 2020;48:D789–96.
77. Wang Q, Zhang L, Yan Z, et al. OScC: an online survival analysis web server to evaluate the prognostic value of biomarkers in cervical cancer. *Future Oncol* 2019;15:3693–9.
78. Yan Z, Wang Q, Sun X, et al. OSbrca: a web server for breast cancer prognostic biomarker investigation with massive data from tens of cohorts. *Front Oncol* 2019;9:1349.
79. Goswami CP, Nakshatri H. PROGgene: gene expression based survival analysis web application for multiple cancers. *J Clin Bioinforma* 2013;3:22.
80. Aguirre-Gamboa R, Gomez-Rueda H, Martínez-Ledesma E, et al. SurvExpress: an online biomarker validation tool and database for cancer gene expression data using survival analysis. *PLoS One* 2013;8:e74250.
81. Gentles AJ, Newman AM, Liu CL, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. *Nat Med* 2015;21:938–45.
82. Mizuno H, Kitada K, Nakai K, et al. PrognoScan: a new database for meta-analysis of the prognostic value of genes. *BMC Med Genomics* 2009;2:18.
83. Liu CJ, Hu FF, Xia MX, et al. GSCALite: a web server for gene set cancer analysis. *Bioinformatics* 2018;34:3771–2.
84. Jang Y, Seo J, Jang I, et al. CaPSSA: visual evaluation of cancer biomarker genes for patient stratification and survival analysis using mutation and expression data. *Bioinformatics* 2019;35:5341–3.

85. Koch A, Jeschke J, Van Criekinge W, et al. MEXPRESS update 2019. *Nucleic Acids Res* 2019;47:W561–5.
86. Goswami CP, Nakshatri H. PROGmiR: a tool for identifying prognostic miRNA biomarkers in multiple cancers using publicly available data. *J Clin Bioinforma* 2012;2:23.
87. Aguirre-Gamboa R, Trevino V. SurvMicro: assessment of miRNA-based prognostic signatures for cancer clinical outcomes by multivariate survival analysis. *Bioinformatics* 2014;30:1630–2.
88. Anaya J. OncoLnc: linking TCGA survival data to mRNAs, miRNAs, and lncRNAs. *PeerJ Computer Science*. 2016: 2:e67.
89. Chen MJM, Li J, Wang Y, et al. TCPA v3.0: an integrative platform to explore the pan-cancer analysis of functional proteomic data. *Mol Cell Proteomics* 2019;18:S15–25.
90. Zhang W, Borchertding N, Bormann NL, et al. TRGAted: a web tool for survival analysis using protein data in the cancer genome atlas. *F1000Research* 2018;7:1235.
91. Gupta S, Chaudhary K, Kumar R, et al. Prioritization of anticancer drugs against a cancer using genomic features of cancer cells: a step towards personalized medicine. *Sci Rep* 2016;6:23857.
92. Gupta S, Chaudhary K, Dhanda SK, et al. A platform for designing genome-based personalized immunotherapy or vaccine against cancer. *PLoS One* 2016;11:e0166372.
93. Tlemsani C, Pongor L, Elloumi F, et al. SCLC-CellMiner: a resource for small cell lung cancer cell line genomics and pharmacology based on genomic signatures. *Cell Rep* 2020;33:108296.
94. Tang Z, Kang B, Li C, et al. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. *Nucleic Acids Res* 2019;47:W556–60.
95. Lauria M, Moyses P, Priami C. SCUDO: a tool for signature-based clustering of expression profiles. *Nucleic Acids Res* 2015;43:W188–92.
96. Wang P, Qin J, Qin Y, et al. ChIP-Array 2: integrating multiple omics data to construct gene regulatory networks. *Nucleic Acids Res* 2015;43:W264–9.
97. Zhang Y, Yu Z, Ban R, et al. DeAnnCNV: a tool for online detection and annotation of copy number variations from whole-exome sequencing data. *Nucleic Acids Res* 2015;43:W289–94.
98. Dereeper A, Homa F, Andres G, et al. SNIPlay3: a web-based application for exploration and large scale analyses of genomic variations. *Nucleic Acids Res* 2015;43:W295–300.

99. Holtgrewe M, Stolpe O, Nieminen M, et al. VarFish: comprehensive DNA variant analysis for diagnostics and research. *Nucleic Acids Res* 2020;48:W162–9.
100. Jia W, Li H, Li S, et al. Oviz-bio: a web-based platform for interactive cancer genomics data visualization. *Nucleic Acids Res* 2020;48:W415–26.
101. Sedova M, Iyer M, Li Z, et al. Cancer3D 2.0: interactive analysis of 3D patterns of cancer mutations in cancer subsets. *Nucleic Acids Res* 2019;47:D895–9.
102. Deng M, Brägelmann J, Kryukov I, et al. FirebrowseR: an R client to the broad Institute's firehose pipeline. *Database* 2017;2017:baw160.
103. Chauvel C, Novoloaca A, Veyre P, et al. Evaluation of integrative clustering methods for the analysis of multi-omics data. *Brief Bioinform* 2020;21:541–52.
104. Tini G, Marchetti L, Priami C, et al. Multi-omics integration- a comparison of unsupervised clustering methodologies. *Brief Bioinform* 2018;20:1269–79.
105. Rappoport N, Shamir R. Multi-omic and multi-view clustering algorithms: review and cancer benchmark. *Nucleic Acids Res* 2018;46:10546–62.
106. Eyal-Altman N, Last M, Rubin E. PCM-SABRE: a platform for benchmarking and comparing outcome prediction AQ9 methods in precision cancer medicine. *BMC Bioinformatics* 2017;18.
107. Nguyen H, Shrestha S, Draghici S, et al. PINSPlus: a tool for tumor subtype discovery in integrated genomic data. *Bioinformatics* 2019;35:2843–6.
108. Dimitrakopoulos C, Hindupur SK, Haf lger L, et al. Network-based integration of multi-omics data for prioritizing cancer genes. *Bioinformatics* 2018;34:2441–8.